NCT07774507 Twenty-four Hour Movement Behaviors and Atherosclerotic Risk
| NCT ID | NCT07774507 |
| Status | Recruiting |
| Phase | — |
| Sponsor | São Paulo State University |
| Condition | Cardiovascular Risk Assessment |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2026-09-01 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This observational study aims to investigate how 24-hour movement behaviors are associated with atherosclerotic risk in adults with rheumatoid arthritis. These behaviors include physical activity, sedentary behavior, and sleep. The main questions it aims to answer are: * Are 24-hour movement behaviors, both individually and in combination, associated with indicators of atherosclerotic risk in adults with RA? * Do changes in 24-hour movement behaviors over 12 months relate to changes in indicators of atherosclerotic risk? Participants will: * Wear activity monitors (accelerometers) continuously for 7 days to measure physical activity, sedentary behavior, and sleep. * Answer questionnaires about their health and lifestyle. * Undergo cardiovascular assessments, body composition measurements, physical fitness tests, and blood tests to measure lipid and inflammatory profile. * Return 12 months later for follow-up assessments. The researchers hope this study will improve understanding of how daily movement behaviors influence cardiovascular health in people with rheumatoid arthritis. The findings may help inform future recommendations to promote healthier movement behaviors and improve cardiovascular risk management in this population.
Eligibility Criteria
Inclusion Criteria: * Medical diagnosis of rheumatoid arthritis. * Age between 18 and 65 years. * Provide written informed consent. * Independence in daily living activities defined as a Katz Index score of 5 or 6 points. Exclusion Criteria: * Acute infectious disease at the time of assessment. * Pregnancy or breastfeeding. * Cognitive impairment identified by the Mini-Mental State Examination according to established cutoff values. * History of cardiovascular disease, including coronary artery disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis, or pulmonary embolism. * Use of uncontrolled vasoactive medication. * Inability to comply with accelerometer wear requirements. * Inability to complete study questionnaires or physical assessments. * Invalid accelerometer data according to the study wear-time criteria.
Contact & Investigator
William R Tebar, PhD
PRINCIPAL INVESTIGATOR
São Paulo State University
Frequently Asked Questions
Who can join the NCT07774507 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Cardiovascular Risk Assessment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07774507 currently recruiting?
Yes, NCT07774507 is actively recruiting participants. Contact the research team at w.tebar@unesp.br for enrollment information.
Where is the NCT07774507 trial being conducted?
This trial is being conducted at Presidente Prudente, Brazil.
Who is sponsoring the NCT07774507 clinical trial?
NCT07774507 is sponsored by São Paulo State University. The principal investigator is William R Tebar, PhD at São Paulo State University. The trial plans to enroll 150 participants.